Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke.
Rovelizumab binds CD18 and has activity against CD18-integrin complexes including the CD11b-CD18 heterodimer[2].
References:
[1]. Jones R. Rovelizumab (ICOS Corp). IDrugs. 2000 Apr;3(4):442-6.
[2]. Qualls JE, et al. A double agent in cancer: stopping macrophages wounds tumors. Nat Med. 2010 Aug;16(8):863-4.
















